Follow the AKUMIN INC. stock price and the full insider trade history of the company, a listed issuer based in United States. Shares are quoted on US US, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, AKUMIN INC. has logged 29 insider filings. The latest transaction was disclosed on 18 July 2023 (Attribution). Among the most active insiders: KRETSCHMER R. DAVID. Every trade is free.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
25 of 29 declarations
Akumin Inc. is a U.S.-based healthcare services company listed on the NASDAQ in the United States, focused on outpatient diagnostic imaging and related services. For French-speaking investors, the company sits in a relatively defensive but operationally sensitive segment of healthcare, where demand is driven by screening, follow-up care, and specialty diagnostics. Akumin operates freestanding imaging centers and serves physicians, hospitals, and health systems by providing radiology and diagnostic solutions in an outpatient setting. ([akumin.com](https://akumin.com/wp-content/uploads/2020-Q4-Annual-Information-Form-20210331-vF.pdf?utm_source=openai)) From a historical perspective, Akumin built its platform around imaging assets and clinical workflow optimization, with a footprint that has been centered on the U.S. market. Company filings describe Akumin as a leading provider of outpatient diagnostic imaging services in the United States, and its headquarters are in Plantation, Florida, which anchors its operational base in the southeastern U.S. ([akumin.com](https://akumin.com/wp-content/uploads/2020-Q4-Annual-Information-Form-20210331-vF.pdf?utm_source=openai)) Its business model is primarily centered on the operation of freestanding imaging facilities and the delivery of diagnostic radiology services such as MRI, CT, X-ray, ultrasound, and other specialized imaging modalities. This model is capital intensive, requiring meaningful investment in advanced equipment, technical staff, and regulatory compliance. At the same time, it benefits from durable underlying demand tied to population aging, chronic disease management, and the increasing importance of early diagnosis. Akumin’s outpatient focus can also be a competitive advantage versus hospital-based imaging, offering greater flexibility and potentially lower-cost access points for patients and referring physicians. ([akumin.com](https://akumin.com/wp-content/uploads/2020-Q4-Annual-Information-Form-20210331-vF.pdf?utm_source=openai)) Competitively, Akumin operates in a fragmented market that includes hospital systems, regional imaging groups, and independent outpatient operators. The company’s value proposition is based on accessibility, geographic proximity, and the ability to provide diagnostic services that are convenient for patients and efficient for referrers. For investors, the key considerations are utilization rates, reimbursement dynamics, operating efficiency, and the strength of relationships with payors and physician networks. ([akumin.com](https://akumin.com/wp-content/uploads/2020-Q4-Annual-Information-Form-20210331-vF.pdf?utm_source=openai)) Recent public disclosures and SEC-related filings indicate that Akumin continues to attract attention in the context of insider transactions and market governance, which is typical for a publicly traded healthcare micro/small-cap profile. The company’s NASDAQ listing reinforces its visibility within the U.S. healthcare services universe and makes it a name that can appear in both fundamental and event-driven investor screens. ([akumin.com](https://akumin.com/wp-content/uploads/Akumin-2021-Management-Information-Circular-vF.pdf?utm_source=openai))